ACTR-15. Safety and preliminary activity of PT2385, a first-in-class HIF2-alpha inhibitor, planned interim analysis of an open label, single-arm phase II study in patients with recurrent glioblastoma - Strowd, R; Ellingson, B; Wen, P (Neuro-Oncol, 2018)
et al.